On the spotlight

Cardiotoxic synergism between anthracyclines, hypomethylating agents and aminopeptidase inhibitors Research Objectives Preclinical optimization of dosage and sequence of anthracyclines, hypomethylating agents, and aminopeptidase inhibitors for the treatment of solid tumors or hematological myeloproliferative disorders Start/End Dates 2014 - 2015 ...

Focus on

Ranolazine to treat early cardiotoxicity induced by antitumor drugs Research Objectives A prospective, low-risk, multicenter Phase IIB study, with competitive recruitment, to evaluate the efficacy and tolerability of ranolazine  versus standard therapies in the treatment of symptoms and/or laboratory indices of early cardiotoxicity induced by standard chemotherap...
Pixantrone pharmacokinetics in the human heart Project objectives The main objective of the project is to characterize the pharmacokinetics of pixantrone in a translational model of human heart exposed to doxorubicin. Information obtained in this model will help to understand cardiac tolerability of pixantrone in non-Hodgkin lymphoma patients with previous exposure tp doxorubicin-ba...
Comparison of Amrubicin, Doxorubicin, Epirubicin, in an Ex Vivo Human Myocardial Strip Model to Evaluate Accumulation, Metabolism and Bioactivation Research Objectives The main objective of this project is to evaluate the pharmacokinetic and metabolic determinants of cardiotoxicity of amrubicin in comparison with doxorubicin and epirubicin in a translational model of ...